Abstract:Cancer vaccines have attracted increasing attention for their application in tumor immunotherapy. DNA vaccines are one of them that have been proven very promising with the advantages of safety, rapid design, and low cost. However, the low stability, ineffective cell internalization, and low immunostimulation hinder their wide application. Thus, developing targeted and safe systems to effectively deliver DNA vaccines becomes a vital step. In this study, we report the development of mannose- and bisphosphonate (BP)-modified calcium phosphate (CP) nanoparticles (NPs) as efficient vaccine delivery vehicles by targeting C-type lectin receptors (CLRs) on antigen-presenting cells (APCs). Using a model antigen ovalbumin (OVA)-encoded plasmid DNA (pOVA) as a model vaccine, we demonstrate that mannose-modified and BP-stabilized CP (MBCP) nanoparticles are mono-dispersed for enhanced uptake by APCs and subsequently induce OVA antigen presentation and immunostimulation. Mice immunized with MBCP-pOVA nanovaccines show a significantly stronger anti-OVA antibody response with a quicker IgG1 and IgG2a antibody production than unmodified NPs. Moreover, MBCP-pOVA immunization significantly inhibits the growth of OVA-expressing E.G7 tumor cells in C57BL/6J mice. Our data collectively suggest that the modifications to enhance the stability and targeting ability of MBCP NPs are essential for effective delivery of DNA vaccines and promote robust anti-tumor immunity.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c01401?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c01401</a>.MBSA synthesis condition optimization, characterization of MBSA, correlation between the mannose amount on MBCP NPs and cellular uptake efficiency, cellular uptake of CP-FITC, MCP-FITC, BCP-FITC, and MBCP-FITC by RAW 264.7 cells, gating strategy for FACS analysis of CD11c<sup>+</sup> BMDCs, cellular uptake of BCP-FITC and MBCP-FITC by BMDCs, determination of the OVA mRNA level after pOVA transfection on RAW 264.7 cells, determination of OVA antigen presentation through MHC-I on DCs by FACS, determination of DC maturation by FACS, bioabsorption efficiency of s.c. injected free pOVA, CP-pOVA, BCP-pOVA, and MBCP-pOVA, anti-OVA serum IgG, IgG1, and IgG2a ELISA test, and images of mouse tumors (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c01401/suppl_file/am1c01401_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Effects of Mannose Modified Chitosan on the Macrophage Uptake of Nanoparticles

Preparation and Evaluation of Mannose Receptor Mediated Macrophage Targeting Delivery System.

Mannose-Modified Chitosan Poly(lactic-co-glycolic acid) Microspheres Act as a Mannose Receptor-Mediated Delivery System Enhancing the Immune Response

Effect of N-trimethyl Chitosan-coated PLGA Nanoparticles on Antigen Cross-presentation

Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier

Novel Mannosylated Chitosan to Target Mannose Receptors-Synthesis,and Its Characterization and Cytotoxicity

Mannose-functionalized antigen nanoparticles for targeted dendritic cells, accelerated endosomal escape and enhanced MHC-I antigen presentation

The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization.

Mannose-Functionalized Biodegradable Nanoparticles Efficiently Deliver DNA Vaccine and Promote Anti-tumor Immunity

Shape Effect of Glyco-Nanoparticles on Macrophage Cellular Uptake and Immune Response.

Preventative Vaccine-Loaded Mannosylated Chitosan Nanoparticles Intended for Nasal Mucosal Delivery Enhance Immune Responses and Potent Tumor Immunity

Functional Polymer/inorganic Hybrid Nanoparticles for Macrophage Targeting Delivery of Oligodeoxynucleotides in Cancer Immunotherapy

Targeted Antigen Delivery to Dendritic Cell Via Functionalized Alginate Nanoparticles for Cancer Immunotherapy

Targeting Delivery of Oligodeoxynucleotides to Macrophages by Mannosylated Cationic Albumin for Immune Stimulation in Cancer Treatment.

Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles.

Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery

Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.

Preparation of OVA‐loaded γ‐PGA/CS nanocomposite delivery vector and its immune response

Binding and Stimulatory Effect of Oligochitosan in Macrophages

Maturation of Dendritic Cells in Vitro and Immunological Enhancement of Mice in Vivo by Pachyman- And/or OVA-encapsulated Poly(d, L-lactic Acid) Nanospheres

Fabrication and optimization of pH-sensitive mannose-anchored nano-vehicle as a promising approach for macrophage uptake